Academic studies consistently show that a reduction in current drug revenues leads to a fall in future research and the number of new drug discoveries.

The Link Between Drug Prices and Research on the Next Generation of Cures

Misusing the “march-in right” provision of the Bayh-Dole Act could negatively impact U.S. life-sciences innovation and result in fewer new drugs.

The Bayh-Dole Act’s Vital Importance to the U.S. Life-Sciences Innovation System

China is challenging the United States for market share and jobs in one of the highest value-added, most innovation-intensive industries—and the risks extend not just to the U.S. economy, but to global biopharma innovation.

China’s Biopharmaceutical Strategy: Challenge or Complement to U.S. Industry Competitiveness?

The rapid growth of large Internet platforms has caused some activists, scholars, and political officials to worry about their impact on competition. These concerns are largely misplaced.

Monopoly Myths: Do Internet Platforms Threaten Competition?

China is striving to become the global leader in biopharmaceuticals, but many of its policy steps are “innovation mercantilist” in nature. This not only is expected to threaten U.S. leadership, but also slow global life sciences innovation, with negative consequences for cures and treatments.

The Impact of China’s Policies on Global Biopharmaceutical Industry Innovation

Blood-based multi-cancer early detection (MCED) technologies hold the promise to revolutionize America’s cancer-screening paradigm, dramatically expanding the range of detectable cancers and identifying them at earlier stages when cancers are more treatable. Policymakers should provide a supportive regulatory and coverage environment.

Seizing the Transformative Opportunity of Multi-cancer Early Detection

The federal government should significantly increase spending on research and development that specifically targets technologies likely to boost productivity in order to spur growth and reduce the budget deficit.

Why Federal R&D Policy Needs to Prioritize Productivity to Drive Growth and Reduce the Debt-to-GDP Ratio

Policymakers should enable entry into the broadband market, but avoid undermining the dynamism of the sector by actively promoting additional competitors.

A Policymaker’s Guide to Broadband Competition

NIH funding is critical to improving health outcomes and reducing the societal costs of illnesses. Congress should increase the NIH budget and then maintain regular, steady increases.

Healthy Funding: The Critical Role of Investing in NIH to Boost Health and Lower Costs

China’s long-standing and rampant “innovation mercantilist” policies harm global innovation by taking market share and revenues from more-innovative foreign competitors, thereby diminishing the resources they can invest in research and development toward further innovation.

Industry by Industry: More Chinese Mercantilism, Less Global Innovation

To advance their goals of economic redistribution, progressives—relying on faulty research, half-truths, and erroneous claims—have delegitimized the long-accepted “consumer welfare” approach to antitrust and generated a groundswell of support for a new “public interest” standard that seeks to protect competitors, especially small businesses.

How Progressives Have Spun Dubious Theories and Faulty Research Into a Harmful New Antitrust Doctrine

Low profit margins keep many small businesses from investing in productivity-enhancing technology, which in turn holds down wages. To break that cycle, there should be a federal program that helps them reap economies of scale and scope by collaborating in areas such as R&D, investment, marketing, and health insurance purchases.

Small Business Boards: A Proposal to Raise Productivity and Wages in All 50 States and the District of Columbia

ITIF’s annual review of books covering technology and innovation issues.

ITIF Summer Reading List 2014

Join ITIF for the release of a new report examining the potential economic gains the United States could reap from biopharma innovation that enables improved diagnosis, treatment, cures, and even prevention of mental and neurological health conditions.

A Trillion-Dollar Opportunity: How Brain Research Can Drive Health and Prosperity

The United States is the leader in life sciences innovation, but that has not always been the case. As global competition intensifies, it needs to continue spurring investment in R&D to stay on top. Rob and Jackie sat down with Stephen Ezell, vice president of global innovation policy at ITIF, to discuss the history of U.S. life sciences innovation and break down R&D costs versus the market prices of innovative biopharmaceuticals.

Innovative Cure For All: How CurASeal’s Plant-Based Technology Advances Bleeding Control and Wound Healing

Related Search Content

The Link Between Drug Prices and Research on the Next Generation of Cures

The Bayh-Dole Act’s Vital Importance to the U.S. Life-Sciences Innovation System

China’s Biopharmaceutical Strategy: Challenge or Complement to U.S. Industry Competitiveness?